Skip to main content
. 2021 Dec 15;44(2):225–234. doi: 10.1016/j.htct.2021.09.020

Table 1.

Main characteristics of the included studies in the meta-analysis.

First Author/Year Country (Ethnicity) Sample Size⁎⁎ Age (range) F/M HC Cancer treatment in total cases
NOS
Surgery Radiotherapy Chemotherapy Targeted therapy Immunotherapy
Yang et al., 2020 China (Asian) 205 63(56-70) 109/96 22 4(2.0) 9(4.4) 31(15.1) 12(5.9) 4(2.0) 8
Tian et al., 2020 China (Asian) 232 64(58-69) 113/119 12 197(84.9) 214(92.2) 32(13.8) 8
Liang et al., 2020 China (Asian) 18 62(56-68) 6/12 1 1(5.6) 0(0.0) 2(11.1) 2(11.1) 1(5.6) 8
Dai et al., 2020 China (Asian) 105 64(55-69) 48/57 9 8(7.6) 13 (12.4) 17(16.2) 4(3.8) 6(5.7) 8
Ali et al., 2020 Pakistan (Asian) 201 45(18–78) 115/86 33 22(10.9) 13(6.5) 146(72.6) 2(1) 0(0.0) 8
Aznab et al., 2020 Iran (Asian) 161 NA NA 64 NA NA NA NA NA 6
Kuderer et al., 2020 Caucasian* 928 66(57-76) 412/516 167 32(3.4) 12(1.3) 160(17.2) 75(8.1) 38(4.1) 9
Lee et al., 2020 UK (Caucasian) 800 69(59-76) 349/449 169 29(3.6) 76(9.5) 281(35.1) 72(9.0) 44(5.5) 9
Russeli et al., 2020 UK (Caucasian) 156 65 66/90 28 NA NA 45(55.6) 5(6.2) 7(8.6) 7
Bhogal et al., 2021 UK (Caucasian) 179 72(61-81) 74/105 52 39(21.8) 34(19.0) 117(65.4) 8
Barlesi et al., 2020 France (Caucasian) 137 61(21-90) 79/58 24 0(0.0) 0(0.0) 48(35.0) 18(13.1) 12(8.8) 8
Albiges et al., 2020 France (Caucasian) 178 60(52-71) 102/76 30 NA NA NA NA NA 6
Mehta et al., 2020 USA (Caucasian) 218 69(10-92) 91/127 54 0(0.0) 49(22.5) 42(19.3) 0(0.0) 5(2.3) 8
Elkrief et al., 2020 Canada (Caucasian) 252 73(4-95) 125/127 20 NA NA NA NA NA 6

NA: Not Available; F/M: Female/Male; HC: Hematological Cancer; NOS: Newcastle-Ottawa Scale.

Europe, USA, Asia;

⁎⁎

All cancer cases with SARS-CoV-2 Infection.